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background
 
Antiresorptive agents are widely used to treat osteoporosis. We report the results of a
multinational randomized, double-blind study, in which postmenopausal women with
osteoporosis were treated with alendronate for up to 10 years.
 
methods
 
The initial three-year phase of the study compared three daily doses of alendronate
with placebo. Women in the original placebo group received alendronate in years 4 and
5 and then were discharged. Women in the original active-treatment groups continued
to receive alendronate during the initial extension (years 4 and 5). In two further exten-
sions (years 6 and 7, and 8 through 10), women who had received 5 mg or 10 mg of
alendronate daily continued on the same treatment. Women in the discontinuation
group received 20 mg of alendronate daily for two years and 5 mg daily in years 3, 4, and
5, followed by five years of placebo. Randomized group assignments and blinding
were maintained throughout the 10 years. We report results for the 247 women who
participated in all four phases of the study.
 
results
 
Treatment with 10 mg of alendronate daily for 10 years produced mean increases in bone
mineral density of 13.7 percent at the lumbar spine (95 percent confidence interval, 12.0
to 15.5 percent), 10.3 percent at the trochanter (95 percent confidence interval, 8.1 to 12.4
percent), 5.4 percent at the femoral neck (95 percent confidence interval, 3.5 to 7.4 per-
cent), and 6.7 percent at the total proximal femur (95 percent confidence interval, 4.4 to
9.1 percent) as compared with base-line values; smaller gains occurred in the group giv-
en 5 mg daily. The discontinuation of alendronate resulted in a gradual loss of effect, as
measured by bone density and biochemical markers of bone remodeling. Safety data,
including fractures and stature, did not suggest that prolonged treatment resulted in
any loss of benefit.
 
conclusions
 
The therapeutic effects of alendronate were sustained, and the drug was well tolerated
over a 10-year period. The discontinuation of alendronate resulted in the gradual loss of
its effects.
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ostmenopausal osteoporosis is a
 
chronic, progressive disorder in which bone
resorption exceeds formation, resulting in
decreased bone mass and deterioration of the mi-
croarchitecture, with consequent decreased bone
strength and increased susceptibility to fracture.
 
1,2
 
Antiresorptive agents are widely used to treat oste-
oporosis. The reduction in the risk of fracture dur-
ing antiresorptive treatment has been related to the
magnitude of changes in bone mineral density and
remodeling activity.
 
3-6
 
 Alendronate, a potent inhib-
itor of bone resorption, has produced sustained re-
ductions in biochemical markers of bone remodel-
ing into the premenopausal range
 
7,8
 
 and consistent
dose-related increases in bone mineral density in a
variety of populations, including elderly women.
 
7-14
 
These effects have been associated with a substan-
tially reduced risk of vertebral and nonvertebral
fractures.
 
3-5,15-20
 
 Bone biopsy and histomorpho-
metric analysis have confirmed that normal bone
structure and mineralization are preserved and that
bone turnover is reduced but not completely sup-
pressed.
 
21
 
 Mineralization is increased but remains
within the normal range.
 
22,23
 
 The favorable effects
of alendronate on bone turnover, mass, and strength
have been confirmed in animal models.
 
24-26
 
In a pair of identical three-year randomized, pla-
cebo-controlled trials, alendronate increased bone
mineral density, decreased bone turnover, and re-
duced the risk of vertebral fracture among women
with osteoporosis.
 
7,8,20
 
 To investigate the effects of
prolonged alendronate therapy as well as its discon-
tinuation, these trials were extended for a total of
10 years. Results for the first seven years have been
described.
 
27,28
 
 In this article we report the results
through the final 3-year extension of the study, in-
cluding 5 years of observation after the discontinu-
ation of alendronate, and the cumulative, 10-year ex-
perience with alendronate.
 
study design
 
Two identical, concurrent multicenter, double-
blind, randomized, placebo-controlled phase 3
studies,
 
7,8,20
 
 designed to permit pooling of results,
enrolled a total of 994 postmenopausal women with
osteoporosis that had been diagnosed on the ba-
sis of the bone mineral density of the lumbar
spine.
 
7,8,20,27
 
Initially, women were randomly assigned to re-
ceive 5, 10, or 20 mg of oral alendronate (Fosamax,
Merck) or placebo daily. Figure 1 shows the treat-
ment assignments for the original study and the ex-
tensions. Women in the placebo group were given
open-label alendronate for years 4 and 5 and then
discharged from the study. The original 5-mg and
10-mg alendronate groups continued to receive the
same doses in all three extensions of the study
(years 4 and 5, 6 and 7, and 8 through 10). Those in
the original 20-mg group received 5 mg for years
3 through 5 and placebo for years 6 through 10 (the
discontinuation group). Their cumulative exposure
to alendronate was similar to the exposure in the
10-mg group after 5 years and to that in the 5-mg
group after 10 years. Investigators and the women
were aware that all long-term participants had re-
ceived alendronate for at least five years and that the
discontinuation group had been switched to place-
bo, but all remained unaware of each woman’s cur-
rent treatment.
The women were instructed to take the study
medication daily, consistent with the instructions in
the product insert. They received 500 mg of calcium
daily. Vitamin D supplements were permitted but
not required.
Twenty-nine of the original 37 centers carried out
all three extension protocols, 17 within the United
States and 12 in other countries. These sites contrib-
uted 804 of the original 994 study participants. Of
the 482 women originally assigned to alendronate at
those sites, 247 (51.0 percent) participated in all
three extensions of the study. Protocols and exten-
sions were approved by institutional review boards.
Each woman gave written informed consent for the
study and each extension.
 
measurements
 
Efficacy End Points
 
The primary end point was the change in bone min-
eral density at the lumbar spine. Secondary end
points were changes in bone mineral density at the
femoral neck, trochanter, total proximal femur (“to-
tal hip”), total body, and forearm regions; changes
in the levels of urinary N-telopeptides of type I col-
lagen, a biochemical marker of bone resorption;
and changes in the levels of serum bone-specific al-
kaline phosphatase and total serum alkaline phos-
phatase, indicators of the rates of bone formation.
Bone mineral density was measured yearly by dual-
energy x-ray absorptiometry (Hologic, Lunar, and
Norland) and interpreted centrally by a quality-
assurance center (Hologic MDM/Synarc) in a blind-
ed fashion.
 
20,27
 
 Biochemical markers were mea-
p
methods
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Figure 1. Treatment Assignments in the Original Three-Year Study and Its Extensions.
 
Of the original 994 women, 804 underwent initial randomization at sites that participated in the third extension of the 
study. Overall, 51 percent of the women in the original three alendronate groups at those sites participated in the third 
extension of the study. The numbers of women participating at those sites in the original study and the first and second 
extensions are shown in parentheses.
994 (804)
Underwent randomization
3-Year Study
1st Extension, Years 4–5
2nd Extension, Years 6–7 
3rd Extension, Years 8–10
86 (54.4% of 158)
Assigned to 10 mg
of alendronate
122 (105)
Assigned to 10 mg
of alendronate
196 (158)
Assigned to 10 mg
of alendronate
Ineligible for
further study
397 (322)
Assigned to
placebo
288 (232)
Assigned to 10 mg
of alendronate
151 (120)
Assigned to 10 mg
of alendronate
78 (47.6% of 164)
Assigned to 5 mg
of alendronate
113 (92)
Assigned to 5 mg
of alendronate
202 (164)
Assigned to 5 mg
of alendronate
145 (112)
Assigned to 5 mg
of alendronate
83 (51.9% of 160)
Assigned to placebo
115 (97)
Assigned to placebo
199 (160)
 Assigned to 20 mg of
alendronate for yr 1–2
and 5 mg for yr 3
143 (114)
Assigned to 5 mg
of alendronate
 
* Plus–minus values are means ±SD. The discontinuation group was treated with 20 mg of alendronate per day for two 
years and then 5 mg daily for three years, followed by placebo for five years. The 10-mg group was treated with 10 mg daily 
for 10 years, and the 5-mg group was treated with 5 mg daily for 10 years. The body-mass index is the weight in kilograms 
divided by the square of the height in meters. BCE denotes bone collagen equivalents, and NA not available.
† The mean base-line T score for the bone mineral density at the lumbar spine was ¡3.1. The entry criterion for bone min-
eral density was 0.80 g per square centimeter or less as measured by a Hologic or Norland densitometer and 0.92 g per 
 
square centimeter or less as measured by a Lunar densitometer. 
 
Table 1. Base-Line Characteristics of Women Enrolled in the Third Extension of the Study and of All Participants 
in the Original Study.*
Characteristic
Discontinuation 
Group 
(N=83)
5-mg Alendronate 
Group 
(N=78)
10-mg Alendronate 
Group
(N=86)
All Original 
Participants
(N=994)
 
Age (yr) 63±6.2 64±7.2 63±6.0 63±7.0
Years since menopause 16±7.6 16±7.7 15±7.7 16±8.2
Body-mass index 25±3.5 24±3.6 24±2.9 24±3.5
Estimated calcium intake (mg/day) 704±459 838±516 747±563 738±539
Existing vertebral fractures (%) 27.2 30.8 17.5 20.6
Bone mineral density at lumbar spine
(g/cm
 
2
 
)†
Hologic or Norland densitometer
Lunar densitometer
0.71±0.1
0.81±0.1
0.70±0.1
0.80±0.1
0.70±0.1
0.82±0.1
0.71±0.1
0.81±0.1
Urinary N-telopeptides of type I collagen 
(nmol of BCE/mmol of creatinine)
71.8 67.1 66.6 NA
Bone-specific alkaline phosphatase (ng/ml) 18.4 16.3 17.8 NA
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sured annually, and specimens were analyzed as they
were received during years 8 through 10, whereas
earlier results were based on batched, archived spec-
imens.
 
7,8,27
 
Evaluation of Fractures
 
Data on morphometrically detected vertebral frac-
tures, clinical fractures, and stature were collected
as safety end points. No formal comparisons were
planned, owing to the limited sample size and the
fact that all the women in this portion of the study
had previously received alendronate. Radiologically
confirmed symptomatic nonvertebral fractures were
considered adverse clinical events, with no attempt
to exclude fractures related primarily to trauma.
Stature was measured annually with Harpenden sta-
diometers.
 
20,27
 
Standardized lateral radiographs of the thor-
acolumbar spine were scheduled at the end of each
extension or at the time of early termination. Ra-
diographs were read locally to facilitate patient care.
Locally diagnosed vertebral fractures were reported
as adverse events. A central evaluation was conduct-
ed after the study was completed (Synarc).
 
28
 
 The ra-
diologist, who was unaware of the subjects’ treat-
ment assignments, evaluated the earliest technically
satisfactory film obtained at the end of year 5 or
thereafter and the latest subsequent film. Updated
digitization methods were used.
 
29
 
 As in the original
study,
 
20
 
 morphometric vertebral fracture was de-
fined by a loss in vertebral height of at least 20 per-
cent and at least 4 mm. The vertebral-fracture results
presented here are the centrally read morphomet-
ric results for years 6 through 10 among women
who continued in the study after year 7 (third ex-
tension).
 
* The percent change is calculated from the start of each interval. The discontinuation group was treated with 20 mg of 
alendronate per day for two years and then 5 mg daily for three years, followed by placebo for five years. The 10-mg group 
was treated with 10 mg daily for 10 years, and the 5-mg group was treated with 5 mg daily for 10 years. CI denotes confi-
dence interval.
† P<0.001 by the within-treatment test of mean percent change=0 for the specified intervals.
‡ P<0.05 by the within-treatment test of mean percent change=0 for the specified intervals.
 
§ P<0.01 by the within-treatment test of mean percent change=0 for the specified intervals. 
 
Table 2. Mean Percent Change in Bone Mineral Density at Specified Intervals.*
Skeletal Site
No. of Women 
Analyzed/Group
Discontinuation 
Group
5-mg Alendronate 
Group
10-mg Alendronate 
Group
 
percent change (95% CI)
 
Lumbar spine
Base line to year 10
Years 6–10
Years 8–10
70–80
72–81
71–81
9.3 (7.5 to 11.1)†
0.3 (¡0.8 to 1.5)
0.2 (¡0.7 to 1.1)
9.3 (7.5 to 11.2)†
2.5 (1.3 to 3.6)†
1.2 (0.2 to 2.1)‡
13.7 (12.0 to 15.5)†
3.7 (2.6 to 4.8)†
2.3 (1.4 to 3.1)†
Femoral neck
Base line to year 10
Years 6–10
Years 8–10
70–77
71–76
71–76
1.5 (¡0.3 to 3.4)
¡2.2 (¡3.9 to ¡0.5)‡
¡1.7 (¡3.0 to ¡0.3)‡
2.8 (0.8 to 4.8)§
1.0 (¡0.8 to 2.7)
0.3 (¡1.2 to 1.7)
5.4 (3.5 to 7.4)†
0.9 (¡0.8 to 2.6)
1.0 (¡0.3 to 2.4)
Trochanter
Base line to year 10
Years 6–10
Years 8–10
69–76
71–76
71–76
5.3 (3.2 to 7.4)†
¡1.0 (¡2.7 to 0.6)
¡1.0 (¡2.4 to 0.4)
4.8 (2.6 to 7.1)†
0.0 (¡1.7 to 1.7)
0.3 (¡1.2 to 1.8)
10.3 (8.1 to 12.4)†
1.0 (¡0.7 to 2.6)
0.9 (¡0.5 to 2.4)
Total hip
Base line to year 10
Years 6–10
Years 8–10
44–49
46–50
46–50
3.4 (1.1 to 5.7)†
¡1.8 (¡3.5 to ¡0.1)‡
¡1.6 (¡2.8 to ¡0.4)‡
2.9 (0.6 to 5.1)‡
0.7 (¡0.9 to 2.3)
¡0.2 (¡1.4 to 1.0)
6.7 (4.4 to 9.1)†
0.8 (¡0.9 to 2.4)
0.1 (¡1.1 to 1.3)
Total body
Base line to year 10
Years 6–10
Years 8–10
52–56
58–64
58–64
1.8 (0.8 to 2.7)†
¡0.6 (¡1.7 to 0.4)
¡0.4 (¡1.1 to 0.4)
1.0 (0.0 to 2.0)
¡0.7 (¡1.8 to 0.3)
¡0.2 (¡0.9 to 0.6)
2.9 (1.9 to 3.9)†
0.4 (¡0.6 to 1.4)
¡0.3 (¡1.0 to 0.4)
Distal 1/3 of forearm
Base line to year 10
Years 6–10
Years 8–10
40–43
44–49
43–45
¡1.4 (¡3.0 to 0.2)
¡2.3 (¡3.8 to ¡0.8)§
¡2.1 (¡3.2 to ¡1.1)†
¡0.8 (¡2.3 to 0.7)
¡0.4 (¡1.8 to 1.0)
¡1.1 (¡2.1 to ¡0.1)‡
1.0 (¡0.6 to 2.6)
¡0.1 (¡1.6 to 1.3)
¡1.0 (¡2.0 to 0.1)
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Change in Lumbar-Spine
BMD (%)
1012 8 6 24 0
0
3
2
1
4
5
6
8
7
9
10
Ye
ar
14
Change in Femoral-Neck
BMD (%)
56 4 3 12 0
0
3
2
1
4
5
6
8
7
9
10
Ye
ar
7
Change in Trochanter
BMD (%)
1012 8 6 24 0
0
3
2
1
4
5
6
8
7
9
10
Ye
ar
Change in Total-Hip
BMD (%)
8 7 6 5 23 04 1
0
3
2
1
4
5
6
8
7
9
10
Ye
ar
Ye
ar
9
Change in Bone-Specific
Alkaline Phosphatase (%)
¡1
0
¡2
0
¡5
0
¡4
0
¡7
0
¡3
0
¡6
0
0
3
2
1
4
5
6
8
7
9
10
0
Change in Total-Body
BMD (%)
23 1 0
0
3
2
1
4
5
6
8
7
9
10
Ye
ar
4
Change in Urinary N-Telopeptides
of Type I Collagen (%)
¡2
0
¡1
0
¡3
0
¡4
0
¡6
0
¡7
0
¡8
0
¡5
0
¡9
0
0
3
2
1
4
5
6
8
7
9
10
Ye
ar
0
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statistical analysis
 
The preplanned analyses pooled data from U.S. and
international centers. The results reported here are
restricted to the 247 women who participated in the
third extension of the study (years 8 through 10).
The primary data are maintained by the sponsor as
required by the Food and Drug Administration and
other regulatory authorities. All authors had access
to a complete set of results. The trial statistician an-
alyzed the data and responded to all queries raised
by the authors.
 
Bone Mineral Density
 
The modified intention-to-treat analysis included
all women with measurements at base line, year 7,
and at least one subsequent year in which a study
drug was given; data from the last evaluation were
carried forward in women who did not complete
year 10. All bone density measurements of vertebrae
at which new lumbar vertebral fractures were detect-
ed were censored for all time points.
 
Markers of Bone Turnover
 
Because analyses of biochemical markers were in-
tended to evaluate pharmacodynamic effects, they
were performed only in women who were in com-
pliance with the protocol (per-protocol analysis).
The effects of treatment are expressed as the percent
change in values (geometric means). The distribu-
tion of changes was normalized by means of a natu-
ral-logarithmic transformation. Analysis of vari-
ance was used to examine treatment effects within
groups, with factors for treatment and study center.
 
Safety
 
The proportions of women with clinical adverse
events and laboratory adverse events were compared
with the use of 95 percent confidence intervals. The
incidence of laboratory values outside predefined
limits was also examined. Analyses of the incidence
of fracture were based on the first fracture within a
specified period. Annualized height loss was esti-
mated primarily from the mean loss during years
6 through 10, according to the modified intention-
to-treat principle; a secondary analysis did not carry
values forward. Using logistic-regression coeffi-
cients derived from the Study of Osteoporotic Frac-
tures, we estimated that the rate of non-vertebral
fracture for a placebo group after a 7-year increase
in age would be 1.26 times the rate observed during
years 1 through 3 (or 1.18 for a five-year age in-
crease), and the expected increase in the risk of
vertebral fracture attributable to advancing age
for a placebo group over the interval from 6 to 10
years would be 1.53 times that observed in years
1 through 3.
 
30,31
 
The characteristics of the 247 women in the third
extension of the study, at the time of their initial
randomization, were similar among the groups and
were similar to those of all 994 participants at base
line. The prevalence of preexisting vertebral frac-
ture and was 30.8 percent in the 5-mg group, 17.5
percent in the 10-mg group, and 27.2 percent in the
discontinuation group. These differences were not
significant. The prevalence of vertebral fracture
results
 
Figure 3 (facing page). Annualized Rate of Height Loss 
(Panel A) and Rate of Nonvertebral Fractures (Panel B) 
during Two Treatment Periods.
 
The discontinuation group was treated with 20 mg of 
alendronate per day for two years and then 5 mg daily for 
three years, followed by placebo for five years. The 10-mg 
group was treated with 10 mg daily for 10 years, and the 
5-mg group was treated with 5 mg daily for 10 years. 
Panel A shows the height loss according to a modified in-
tention-to-treat analysis, without adjustment for age. Dur-
ing years 6 through 10, the mean height loss was 7.0 mm 
(95 percent confidence interval, 3.5 to 10.4) in the discon-
tinuation group, 7.2 mm (95 percent confidence interval, 
3.5 to 10.9) in the 5-mg group and 5.6 mm (95 percent 
confidence interval, 2.5 to 8.7) in the 10-mg group. An 
analysis that included only women who completed the 
study, also without adjustment for age, showed slightly 
greater decreases in height in the 5-mg group and the dis-
continuation group. On the basis of either analysis, height 
loss in the 10-mg group was similar to that among all alen-
dronate-treated subjects in the first three years. 
Panel B shows the rate of nonvertebral fracture per 100 
subject-years. During the initial three years, 10.7 percent 
of women originally assigned to placebo and 8.5 percent 
of women in the pooled alendronate groups had a non-
vertebral fracture; the incidence of fracture was similar 
among the alendronate groups. Rates for years 6 through 
10 are shown. During years 8 through 10, the proportion 
of women with a first nonvertebral fracture was 12.0 per-
cent in the discontinuation group, 11.5 percent in the 
5-mg group, and 8.1 percent in the 10-mg group, respec-
tively; data were available for 247 women. Thus, the pro-
portion of women with fractures in the 10-mg group was 
similar to that for the alendronate groups as a whole dur-
ing years 1 through 3. The estimate for the placebo group 
represents the calculated incidence of fracture that 
would have been expected if our original placebo group 
had continued untreated. Data on years 1 through 3 are 
from Liberman et al.
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was 20.6 percent in the original study population at
base line (Table 1).
 
bone mineral density
 
Bone mineral density at the lumbar spine continued
to increase during years 6 through 10 and 8 through
10 in both alendronate groups (Table 2 and Fig. 2A).
The mean cumulative increase after 10 years of the
10-mg daily dose was 13.7 percent, as compared
with the base-line value; smaller gains occurred in
the 5-mg group. During years 6 through 10, the
alendronate groups had no significant decline in
bone mineral density at any skeletal site. In the dis-
continuation group, bone mineral density at the
lumbar spine did not change significantly after year
5; significant decreases occurred at the total hip,
femoral neck, and forearm, but bone mineral den-
sity at the lumbar spine, trochanter, total hip, and
total body remained significantly above base-line
values at year 10 (Table 2 and Fig. 2A through 2E).
The vast majority of women who received alen-
dronate had increases in bone mineral density dur-
ing the 10-year study. For example, 89 percent of
women who took the 10-mg dose daily had an in-
crease (as indicated by a change greater than 0) in
bone mineral density at the total hip.
 
markers of bone remodeling
 
In the initial study, alendronate reduced the levels of
markers of bone remodeling to stable nadir levels in
H
ei
gh
t L
os
s 
(m
m
/y
r)
1.4
1.6
1.2
1.0
0.6
0.4
0.8
0.2
0.0
Discontinuation
Group
(N=65)
5-mg
Alendronate
Group
(N=57)
10-mg
Alendronate
Group
(N=73)
Placebo
Group
(N=397)
Original
Alendronate
Group
(N=597)
Years 1–3 Years 6–10
1.8
W
om
en
 w
ith
 N
on
ve
rt
eb
ra
l F
ra
ct
ur
e
(n
o.
/1
00
 s
ub
je
ct
-y
r)
3
4
2
1
0
Placebo
Group
(N=397)
Original
Alendronate
Group
(N=597)
Discontinuation
Group
(N=83)
Estimate
for Placebo
Group
5-mg
Alendronate
Group
(N=78)
10-mg
Alendronate
Group
(N=86)
Years 1–3 Years 6–10
5
A
B
The New England Journal of Medicine 
Downloaded from nejm.org at VIRGINIA COMMONWEALTH UNIV on January 22, 2015. For personal use only. No other uses without permission. 
 Copyright © 2004 Massachusetts Medical Society. All rights reserved. 
 n engl j med 
 
350;12
 
www.nejm.org march 
 
18
 
, 
 
2004
 
The
 
 new england journal 
 
of
 
 medicine
 
1196
 
the normal premenopausal range.
 
7,8
 
 This effect was
sustained through 10 years of treatment (Fig. 2F
and 2G). Mean levels of urinary N-telopeptides of
type I collagen in the 10-mg group declined from
66.6 nmol of bone collagen equivalent per millimole
of creatinine at base line to 22.0 nmol per millimole
at the end of year 10 (the latter is similar to the pub-
lished mean value for premenopausal women
 
32
 
).
During years 8 through 10, levels of urinary N-telo-
peptides of type I collagen remained stable in alen-
dronate groups. The mean serum bone-specific al-
kaline phosphatase level in the 10-mg group was
17.8 ng per milliliter at base line and 9.1 ng per
milliliter at the end of year 10 (which is also similar
to the published mean value for premenopausal
women
 
32
 
). After the discontinuation of alendro-
nate, levels of markers of bone remodeling in-
creased within a year,
 
27
 
 but the mean values re-
mained below base-line values. Although the mean
total alkaline phosphatase levels were unchanged,
small increases in mean serum bone-specific alka-
line phosphatase values were measured during the
final year of the study (Fig. 2G).
 
skeletal safety
 
Vertebral Fracture
 
During the initial three-year study, 6.2 percent of
women in the placebo group had new morphomet-
ric vertebral fractures, as compared with 3.2 per-
cent in the pooled alendronate groups (P=0.03)
 
20
 
;
proportions among the three alendronate groups
were similar. For this analysis, 228 women could be
evaluated for years 6 through 10. During those five
years, the proportions of women with new morpho-
metric vertebral fractures did not differ significantly
among the three groups: 6.6 percent in the discon-
tinuation group, 13.9 percent in the 5-mg group,
and 5.0 percent in the 10-mg group. These propor-
tions are difficult to compare with those for years
1 through 3 owing to the difference in the lengths
of the observation periods. The rates of fracture
(e.g., the number per 100 subject-years) could not
be calculated accurately because the date of occur-
rence within the observation interval was usually
not known.
 
Stature
 
Height loss in the 10-mg group during years
6 through 10 was similar to that among all alen-
dronate-treated women during the first three years.
The height loss was slightly but not significantly
greater in the 5-mg and discontinuation groups
than in the 10-mg group during years 6 through 10
(Fig. 3A).
 
Nonvertebral Fracture
 
In years 6 through 10, the rate of radiologically con-
firmed nonvertebral fractures in the 10-mg group
was similar to that in the pooled alendronate groups
during the first three years of the study (Fig. 3B).
No insufficiency fractures or instances of fracture
malunion were reported.
 
general safety and tolerability
 
During years 8 through 10, the safety profiles were
similar among all three groups (Table 3). Four wom-
en died during years 8 through 10, all of whom were
in the 5-mg group. None of the deaths were attribut-
ed to alendronate. The incidence of all upper gas-
trointestinal adverse events was similar among the
three groups. One or two women in each group
withdrew because of upper gastrointestinal adverse
events. During years 8 through 10, 30 to 36 percent
of women in each treatment group used aspirin,
and 41 to 53 percent used nonsteroidal or glucocor-
ticoid antiinflammatory agents. There appeared to
be no adverse interaction between these drugs and
alendronate.
Alendronate appeared to be effective over the 10-
year period of the study. The observed increases in
bone mineral density at the lumbar spine during
long-term alendronate therapy are consistent with
models predicting that a positive bone-remodel-
ing balance and increased secondary mineralization
would be contributing factors.
 
33,34
 
 Nonstructural
calcifications may have contributed to the measured
increase in bone mineral density at the lumbar spine
but are unlikely to explain most of the effect.
 
35,36
 
After an initial reduction, the levels of bone-
remodeling markers remained essentially stable
within the premenopausal range during treatment.
After the discontinuation of alendronate therapy,
levels of these markers increased but remained be-
low pretreatment levels. The small increase in se-
rum bone-specific alkaline phosphatase levels dur-
ing year 10 in all three groups could be due to subtle
changes in the performance of the assay, particular-
ly in view of the stable levels of total alkaline phos-
phatase.
The long retention time of alendronate in bone
 
37
 
may result in gradual recycling and some residual
discussion
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suppression of bone resorption.
 
38
 
 The partial main-
tenance of the drug’s effect after the discontinuation
of therapy could be useful, particularly if adherence
to therapy is inconsistent.
 
39
 
 In contrast, the discon-
tinuation of estrogen results in a relatively rapid de-
cline in bone mineral density and an increase in
bone turnover.
 
40-45
 
 Accelerated bone resorption
may cause microstructural weakness.
 
3
 
 This may ex-
plain the rapid diminution of antifracture efficacy
after estrogen therapy is stopped.
 
46
 
 Increased rates
of bone turnover and losses in bone mineral density
also occur after the withdrawal of raloxifene.
 
43
 
We used the incidence of fracture as a safety mea-
sure rather than an efficacy measure. Varying inter-
vals between spinal radiographs, a change in analy-
sis center, and the small number of events limit the
interpretation of the incidence of vertebral fracture.
Increases in age further confound comparison be-
tween the initial and final intervals. We calculated
the increases in the incidence of fracture that would
have been expected if our original placebo group
had continued untreated. Our observations do not
suggest any association between prolonged use
of alendronate and an excess risk of fracture. Al-
though the differences were not statistically signif-
icant, the fewest morphometric vertebral fractures,
least height loss, and lowest rate of nonvertebral
fractures occurred in the group given 10 mg of
alendronate, which also had the greatest cumulative
exposure to alendronate. Thus, there was no indi-
cation of any adverse cumulative effect. Other indi-
cators of safety and tolerability were similar among
the groups during years 8 through 10.
In summary, continuous treatment with 10 mg of
alendronate daily for 10 years was associated with
sustained therapeutic effects on bone density and
remodeling, with no indication that the antifracture
efficacy of the drug was diminished. The discontin-
uation of alendronate resulted in a gradual diminu-
tion of effect. Because each therapeutic agent used
for the treatment of osteoporosis may have unique
characteristics, our observations should not be as-
sumed to apply to other treatments for osteoporosis.
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Table 3. Adverse Events Reported during Years 8 through 10.*
Adverse Event
Discontinuation 
Group 
(N=83)
5-mg 
Alendronate Group 
(N=78)
10-mg 
Alendronate Group 
(N=86)
 
number of women (percent)
 
Any clinical event
≥1
Serious
Cause of discontinuation
77 (92.8)
18 (21.7)
7 (8.4)
74 (94.9)
25 (32.1)
5 (6.4)
77 (89.5)
18 (20.9)
4 (4.7)
Any upper gastrointestinal event
≥1
Serious
Cause of discontinuation
20 (24.1)
1 (1.2)
2 (2.4)
11 (14.1)
1 (1.3)
1 (1.3)
24 (27.9)
0 
2 (2.3)
Esophageal event
≥1
Dysphagia
Erosive esophagitis
Esophagalgia
Esophagitis
Odynophagia
6 (7.2)
2 (2.4)
2 (2.4)
0 
1 (1.2)
1 (1.2)
1 (1.3)
0 
1 (1.3)
0 
0 
0 
2 (2.3)
0 
0 
1 (1.2)
1 (1.2)
0 
Perforations, ulcers, or bleeding
Duodenal ulcer 0 1 (1.3) 0 
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